Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Lafayette

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Nephrology (Carlton, Vic.)|September 27, 2024
Utilizing complement inhibition in IgA nephropathyRichard Lafayette
Med (New York, N.Y.)|January 10, 2026
Current trial landscape of IgA nephropathy therapyJackson Kim, Fahmeedah Kamal, Richard Lafayette
Seminars in Nephrology|March 14, 2025
Current Biomarkers of IgA NephropathyFahmeedah Kamal, Jackson Kim, Richard Lafayette
Kidney International|December 27, 2025
Modern Challenges in Infection Prevention: Encapsulated Organisms in the era of novel complement inhibitorsAyman Al Jurdi, Camille N Kotton, Richard Lafayette
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 30, 2009
Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patientsKevin Chan, John Moran, Mark Hlatky, et al.
Clinical Kidney Journal|May 15, 2026
Simultaneous or Sequential Treatment of IgA Nephropathy - Specific Disease Drivers and Non-specific Consequences of Nephron Loss?Jonathan Barratt, Jürgen Floege, Carmine Zoccali, et al.
Advances in Kidney Disease and Health|July 14, 2024
Membranoproliferative Glomerulonephritis Pattern of InjurySamuel Mon-Wei Yu, Margaret Deoliveira, Miriam Chung, et al.
Frontiers in Nephrology|February 16, 2024
The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapiesChee Kay Cheung, Jonathan Barratt, Adrian Liew, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 22, 2023
The Association of Class I and II Human Leukocyte Antigen Serotypes With End-Stage Kidney Disease Due to Membranoproliferative Glomerulonephritis and Dense Deposit DiseaseHalimat Afolabi, Bing M Zhang, Michelle O'Shaughnessy, et al.
Kidney International Reports|January 11, 2020
An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of ProgressionLadan Zand, Pietro Canetta, Richard Lafayette, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Nephrology (Carlton, Vic.)|September 27, 2024
Utilizing complement inhibition in IgA nephropathyRichard Lafayette
Med (New York, N.Y.)|January 10, 2026
Current trial landscape of IgA nephropathy therapyJackson Kim, Fahmeedah Kamal, Richard Lafayette
Seminars in Nephrology|March 14, 2025
Current Biomarkers of IgA NephropathyFahmeedah Kamal, Jackson Kim, Richard Lafayette
Kidney International|December 27, 2025
Modern Challenges in Infection Prevention: Encapsulated Organisms in the era of novel complement inhibitorsAyman Al Jurdi, Camille N Kotton, Richard Lafayette
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 30, 2009
Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patientsKevin Chan, John Moran, Mark Hlatky, et al.
Clinical Kidney Journal|May 15, 2026
Simultaneous or Sequential Treatment of IgA Nephropathy - Specific Disease Drivers and Non-specific Consequences of Nephron Loss?Jonathan Barratt, Jürgen Floege, Carmine Zoccali, et al.
Advances in Kidney Disease and Health|July 14, 2024
Membranoproliferative Glomerulonephritis Pattern of InjurySamuel Mon-Wei Yu, Margaret Deoliveira, Miriam Chung, et al.
Frontiers in Nephrology|February 16, 2024
The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapiesChee Kay Cheung, Jonathan Barratt, Adrian Liew, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 22, 2023
The Association of Class I and II Human Leukocyte Antigen Serotypes With End-Stage Kidney Disease Due to Membranoproliferative Glomerulonephritis and Dense Deposit DiseaseHalimat Afolabi, Bing M Zhang, Michelle O'Shaughnessy, et al.
Kidney International Reports|January 11, 2020
An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of ProgressionLadan Zand, Pietro Canetta, Richard Lafayette, et al.
Pageof 5